The Efficacy And Cognitive Impairment Of Modified Electroconvulsive Therapy
NCT ID: NCT02066077
Last Updated: 2018-04-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
280 participants
INTERVENTIONAL
2013-01-01
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
2. To determine the influencing factors and reversibility of the cognitive impairment caused by MECT;
3. To determine the duration of efficacy of MECT and its affecting factors.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness of MST Versus ECT for Major Depressive Episode
NCT06409325
Predict MDE Outcomes After MST
NCT03841019
Investigating How the RECT Impacts Brain Functional States Through the ACC-cerebellar Loop
NCT06912191
Magnetic Seizure Therapy (MST) for Treatment Resistant Depression, Schizophrenia, and Obsessive Compulsive Disorder
NCT01596608
Electroencephalography-based Precise Repetitive Transcranial Magnetic Stimulation Treatment
NCT06385405
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bilateral frontal and propofol
During the MECT treatment, electrodes are placed at bilateral frontal, with propofol 2mg/kg to Induce anesthesia.
Propofol
Bilateral frontal MECT
Bilateral frontal and etomidate
During the MECT treatment, electrodes are placed at bilateral frontal, with etomidate 0.3mg/kg to Induce anesthesia.
Etomidate
Bilateral frontal MECT
Standard-therapy Group
During the MECT treatment, electrodes are placed at bilateral temporal, with etomidate 0.3mg/kg to Induce anesthesia.
Etomidate
Bilateral temporal MECT
Bilateral temporal and propofol
During the MECT treatment, electrodes are placed at bilateral temporal, with propofol 2mg/kg to Induce anesthesia.
Propofol
Bilateral temporal MECT
Bilateral temporal and etomidate
During the MECT treatment, electrodes are placed at bilateral temporal, with etomidate 0.3mg/kg to Induce anesthesia.
Etomidate
Bilateral temporal MECT
The right temporal and propofol
During the MECT treatment, electrodes are placed at the right temporal, with propofol 2mg/kg to Induce anesthesia.
Propofol
The right temporal MECT
The right temporal and etomidate
During the MECT treatment, electrodes are placed at the right temporal, with etomidate 0.3mg/kg to Induce anesthesia.
Etomidate
The right temporal MECT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Etomidate
Propofol
Bilateral temporal MECT
The right temporal MECT
Bilateral frontal MECT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Meet International Classification of Diseases-10(ICD-10) diagnostic criteria for depression
* Scored 18 or above on the HAM-D Scale which included 17 items
* Clinical Global Impression(CGI)-severity score ≥ 4
* Provided written informed consent
Exclusion Criteria
* Meet other diagnosis criteria in Diagnostic and Statistical Manual of Mental Disorders-IV-Test Revision(DSM-IV-TR) Axis I
* With a history of acute or chronic renal failure, liver cirrhosis or active hepatopathy
* With clinically significant abnormal results of laboratory test, which are considered to have impact on treatment efficacy and the safety of participants
* With a history of severe or unstable physical disease including nervous system disease and myocardial infarction
* Undergoing alcoholism or alcohol (or substance) abuse during 30 days or 6 months before the trial
* With no response to previous ECT treatment
* Received transcranial magnetic stimulation treatment in the last 6 months
* Allergic to propofol, etomidate and succinylcholine chloride
* During pregnancy or lactation
* With a history of stroke in the last month
* Enrolled in any other clinical trial 30 days prior to the baseline
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tongji Hospital
OTHER
Huashan Hospital
OTHER
Shanghai Mental Health Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai Mental Health Center
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SHDC12012109
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.